Viking Therapeutics has announced positive results from its Phase Ib clinical trial of VK0214, a thyroid hormone receptor ...

One of the unexplored frontiers in ALD is the enhancement of ALD reactions using non-thermal methods. We are exploring the ability of low energy electrons to enhance ALD reactions. The goal is to ...

In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked ...